Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia

The Journal of Infection
Cheol-In KangJennifer Perera

Abstract

This study was performed to identify risk factors for the development of bacteremic pneumonia and to evaluate the impact of bacteremia on the outcome of pneumococcal pneumonia. Using a database from a surveillance study of community-acquired pneumococcal pneumonia, we compared data of the bacteremic group with that of the non-bacteremic group. Among 981 adult patients with pneumococcal pneumonia, 114 (11.6%) patients who had documented pneumococcal bacteremia were classified into the bacteremic group. In a multivariable analysis, use of immunosuppressant drugs, younger age (<65 years), and DM were independent risk factors associated with the development of bacteremic pneumonia among patients with pneumococcal pneumonia (all P < 0.05). The mortality rate was significantly higher in the bacteremic group than in the non-bacteremic group (28.6% vs. 8.5%; P < 0.001). The multivariable analysis revealed that concomitant bacteremia was one of the significant risk factors associated with mortality (OR, 2.57; 95% CI, 1.24-5.29), along with cerebrovascular disease and presentation with septic shock (all P < 0.05). Bacteremia was a common finding in pneumococcal pneumonia and was associated with a higher mortality rate. Several clinical v...Continue Reading

References

Aug 15, 2000·Medicine·Daniel M MusherE Solomon
Apr 30, 2003·The Journal of Infectious Diseases·Kevin B LauplandH Dele Davies
May 1, 1964·Annals of Internal Medicine·R AUSTRIAN, J GOLD
Nov 25, 2003·American Journal of Respiratory and Critical Care Medicine·Mark L MeterskyPeter M Houck
Feb 6, 2004·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Jien-Wei LiuYen-Fen Huang
Sep 20, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel M MusherMaria C Rodriguez-Barradas
Jul 27, 2007·Scandinavian Journal of Infectious Diseases·Jae Hyun ChoKang-Won Choe
Jan 22, 2008·European Journal of Internal Medicine·Francisco JoverJaime Merino
Jun 4, 2008·Medicine·Catherine M BerjohnJ P Metlay
Oct 18, 2008·Epidemiology and Infection·J H FloryJ P Metlay
Jun 27, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Miquel FalgueraNAC-CALIDAD (Proyecto Integrado de Investigación de la Sociedad Española de Patología del Aparato Respiratorio sobre Infecci
Jan 21, 2010·Scandinavian Journal of Infectious Diseases·José Garnacho-MonteroJavier Aznar-Martín
May 15, 2010·The American Journal of Emergency Medicine·Rafael PerellóAsunción Moreno
Aug 19, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Daniel M WeinbergerMarc Lipsitch

Citations

Sep 26, 2013·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C-I KangANSORP Study Group
Nov 5, 2013·Medicina clínica·Pere Tudela, Josep Maria Mòdol
Dec 29, 2013·Chest·Simone GattarelloCommunity-Acquired Pneumonia en la Unidad de Cuidados Intensivos II Study Investigators*
Feb 2, 2015·Revista brasileira de hematologia e hemoterapia·Matilde Boada BurutaranLilian Diaz
Aug 1, 2014·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·S P van MensB J M Vlaminckx
Mar 4, 2015·Open Forum Infectious Diseases·Mathieu BlotLionel Piroth
Nov 23, 2013·Infection & chemotherapy·Cheol-In Kang, Jae-Hoon Song
Jul 13, 2019·The Journal of Infection·Stefano AlibertiGLIMP investigators

Related Concepts

Streptococcal Pneumonia
Streptococcus pneumoniae
Multivariate Analysis
Bacteremia
Community-Acquired Infections
Cerebrovascular Disorders
Diabetes Mellitus
Immunosuppressive Agents
Pneumonia
Population Surveillance

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Related Papers

Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
J R BlancoJ San Román
Anales españoles de pediatría
E Bernaola IturbeGrupo de Estudio de Enfermedad Invasora Neumocócica en el País Vasco-Navarra
© 2021 Meta ULC. All rights reserved